Tod Woolf

Background

About Tod Woolf

Innovative developer of biomedical technologies. Experienced in Academic Technology Transfer, BD, IP management & translation of scientific platforms into products. Communication skills demonstrated by publications, presentations including keynote addresses and team building. Generated >$250M in grant, alliance, licenses & equity revenues. Co-developed Therapeutic Editing™(1995), MOD mRNA Therapeutics™ & Vax platform (1997), STEALTH RNAi™(2003), Self-Delivering RNAi™(2009). Co-founded Sequitur, acquired by Invitrogen and RXi (public, 2008), ETAGEN & participated in formation of more than twenty other startups. Served as CBO at X-Body (acquired by Juno). KEY PATENTS, PUBS & PRODUCTS 1) THERAPEUTIC RNA EDITING™: Pursued by ETAGEN, ProQR, Beam, Locana & Korro Woolf, et al “Towards the therapeutic editing of mutated RNA sequences” PNAS, 1995 2) mRNA THERAPEUTICS™ and Vaccines: Early patent application on MOD mRNA for protein replacement & vaccines. Pursued by Arbutus, Moderna, BioNTech & Translate Bio • Woolf, et al “Sense mRNA Therapeutics” US Pat App 60/059371 1997 3) GENOME EDITING BY BASE MOD: • Woolf “Therapeutic repair of mutated nucleic acid sequences” Nature Biotech 1998 • Woolf, et al “To Cleave or not to Cleave” Nature Rev DD 2017 4) GENOME EDITING WITHOUT PROGRAMMABLE NUCLEASES: First to describe modified single-stranded DNA as guide/donor for genome editing. Pursued by ETAGEN & TruCode • “Therapeutic repair of mutated nucleic acid sequences” Woolf, Nature Biotech 1998 • Woolf et al “Compositions and methods for editing nucleic acids” US17/31381 2014 5) STEALTH™ RNAi (DICER SUBSTRATES): First to commercialize STEALTH RNAi pursued by Sequitur (now Thermo Fisher) and Dicerna • Woolf et al “Double-stranded oligos” US Pat. 10,106,793, 2002 • publications used STEALTH RNAi 6) SELF-DELIVERING RNAi™ 1st oligo delivery conjugate to enter clinical trials (2008). Currently pursued by RXi, UMMC & Advirna. • Woolf, et al “Reduced size self-delivering RNAi compounds” US Patent 10,041,073 2008 • Lapierre et al “Potent and systematic RNAi mediated silencing with single oligo compounds” RNA 2011 7) NEXTGEN GAPMER ANTISENSE Sequitur, Atugen & Oligo Ther,$30M sales. • Woolf et al “3 Component Chimeric Antisense Oligos” US Patent 5849902,1996 • Used to discover the Alzheimer’s beta-secretase Nature and Science 8) OFF-TARGET EFFECTS. 1st to show off-target antisense by seed sequences. • Woolf, Melton, Jennings “Specificity of antisense oligos in vivo” PNAS 1992